EphA8 is a prognostic marker for epithelial ovarian cancer
Metrics: PDF 2124 views | HTML 2026 views | ?
Xiaoqin Liu1,*, Yunzhao Xu2,*, Qin Jin3, Wei Wang3, Shu Zhang3, Xudong Wang4, Yuquan Zhang2, Xujuan Xu1, Jianfei Huang3
1Department of Nursing, Nantong University, Nantong 226001, Jiangsu, China
2Department of Obstetrics and Gynecology, Nantong University Affiliated Hospital, Nantong 226001, Jiangsu, China
3Department of Pathology, Nantong University Affiliated Hospital, Nantong 226001, Jiangsu, China
4Department of Laboratory Medicine, Nantong University Affiliated Hospital, Nantong 226001, Jiangsu, China
*These authors contributed equally to this work
Xujuan Xu, e-mail: [email protected]
Jianfei Huang, e-mail: [email protected]
Keywords: EphA8, human epithelial ovarian cancer (EOC), immunohistochemistry, qRT-PCR, prognosis
Received: January 05, 2016 Accepted: February 15, 2016 Published: March 09, 2016
EphA8 is one of the Eph receptors in the Eph/ephrin receptor tyrosine kinase (RTK) subfamily. During tumorigenesis, EphA8 is involved in angiogenesis, cell adhesion and migration. In this study, we determined the mRNA and protein expression levels of EphA8 in cancerous and normal ovarian tissue samples by quantitative reverse transcription PCR (qRT-PCR) (N = 60) and tissue microarray immunohistochemistry analysis (TMA-IHC) (N = 223) respectively. EphA8 protein levels in cancer tissues were correlated with epithelial ovarian cancer (EOC) patients’ clinical characteristics and overall survival. Both EphA8 mRNA and protein levels were significantly higher in EOC tissues than in normal or benign ovarian tissues (all P < 0.05). High EphA8 protein level was associated older age at diagnosis, higher FIGO stage, positive lymph nodes, presence of metastasis, positive ascitic fluid, and higher serum CA-125 level. High EphA8 protein level is an independent prognostic marker in EOC. We conclude that EphA8 acts as an oncogene in EOC development and progression. Detection of EphA8 expression could be a useful prognosis marker and targeting EphA8 represents a novel strategy for EOC treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.